Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor , Hydrophobic Chromatography Process in Subjects With Cystic Fibrosis

על הניסוי

This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and older with cystic fibrosis (CF). The treatment duration in this study was intended to provide multi-dose safety information prior to proceeding to longer durations of exposure.

צפו ב-NCT01684410 ב-ClinicalTrials.gov ←

קישורים קשורים